VEGFA and age-related macular degeneration: Increased uptake of anti-VEGF agents among eye care providers and educators is critical because anti-VEGF agents have demonstrated robust efficacy among certain eye diseases, such as DR [36], and are considered guideline-concordant care for AMD, DR/DME, and RVO [10–13].